INTRODUCTION {#s1}
============

The transcription factor Sox2 belongs to the SoxB1 family (Sox1-3), which collectively are expressed in the majority, if not all, neural precursor cells in the central nervous system (CNS) ([@DEV153791C77]). Moreover, Sox2 is necessary for the pluripotency of embryonic stem cells, and *Sox2* knockout mice have been shown to be early embryonic lethal ([@DEV153791C2]; [@DEV153791C64]). Later in neural development, Sox2 becomes restricted to neural stem and early progenitor cells, in which it acts to maintain an undifferentiated cell state ([@DEV153791C10]; [@DEV153791C14]; [@DEV153791C32]; [@DEV153791C34]; [@DEV153791C39]). The crucial role that Sox2 plays in self-renewal and differentiation of neural precursors has been reviewed ([@DEV153791C66]; [@DEV153791C77]; [@DEV153791C76]). In slowly dividing stem cells, high levels of Sox2 expression repress pro-proliferative genes, whereas reduced levels of Sox2 results in a transition to a proliferative progenitor cell state ([@DEV153791C34]). At postnatal stages, Sox2 marks neural stem cells within the three neurogenic niches of the head region: the hippocampus, the subventricular zone (SVZ) and the olfactory epithelium ([@DEV153791C18]; [@DEV153791C33]; [@DEV153791C85]; [@DEV153791C99]). Several studies have examined the requirement and role of Sox2 in the CNS (reviewed by [@DEV153791C22]; [@DEV153791C76]; [@DEV153791C81]; [@DEV153791C84]), whereas less is known about its function in the peripheral nervous system (PNS).

The olfactory epithelium, which belongs to the PNS, expresses Sox2 both during development and at adult stages ([@DEV153791C33]; [@DEV153791C53]; [@DEV153791C74]). The nasal epithelium is derived from the olfactory placode, a transient thickening of the embryonic head ectoderm in proximity to the ventral telencephalon. During development, the nasal epithelium is divided into a sensory domain and a respiratory region ([@DEV153791C16]; [@DEV153791C60]). The sensory epithelium produces several cell types, including olfactory sensory neurons, whereas the respiratory epithelium generates, among others, non-neural cells producing mucus that removes particles from inhaled air. The olfactory epithelium is one of few tissues, together with the hippocampus and SVZ, that maintain adult neurogenesis ([@DEV153791C9]; [@DEV153791C49]). The role Sox2 plays in the development of the olfactory epithelium remains to be determined.

Olfactory neurogenesis begins already at the placodal stage and involves the generation of post-mitotic neurons ([@DEV153791C28]; [@DEV153791C59]), which are among the first neurons generated in the vertebrate nervous system. During olfactory neurogenesis, distinct genes are upregulated in a sequential manner in the neuronal lineage, in the same conserved programme as for neurogenesis within the CNS. This includes *Hes5* in progenitor cells, *Ngn1* (also called *Neurog1*) in immediate neuronal precursor cells, *NeuroD* (*Neurod1*) in cells committed to leave the cell cycle, and *HuC/D* (*Elavl3/4*) and class III β-Tubulin (*Tubb3*) in post-mitotic neurons ([@DEV153791C13], [@DEV153791C12]; [@DEV153791C29]; [@DEV153791C59]; [@DEV153791C91]; [@DEV153791C93],[@DEV153791C94]). However, *Ngn1* expression is maintained in both differentiated *Neurod1* cells and post-mitotic neurons before being downregulated ([@DEV153791C59]). The roles of distinct transcription factors necessary for cell cycle exit, downregulation of progenitor proteins and upregulation of neuron differentiation markers have been well characterized (reviewed by [@DEV153791C6]; [@DEV153791C44]; [@DEV153791C79]; [@DEV153791C90]). Neurogenesis has been shown to involve similar molecular mechanisms at embryonic and adult stages, both in the olfactory epithelium and in the brain, across several vertebrate species ([@DEV153791C8]; [@DEV153791C51]; [@DEV153791C56]; [@DEV153791C61]). Thus, the relatively simple and easily accessible olfactory epithelium provides a good model system for studying the interactions of signalling molecules and downstream transcription factors, and how they act during neurogenesis ([@DEV153791C11]; [@DEV153791C27]; [@DEV153791C45]; [@DEV153791C48]; [@DEV153791C61]; [@DEV153791C72]; [@DEV153791C89]; [@DEV153791C93]). The function of Sox2 in neurogenesis in the olfactory epithelium has not yet been addressed.

In this study, we have analysed the role of *Sox2* in the development of the olfactory epithelium and neurogenesis within. To examine this, we used a conditional *Foxg1-* (previously known as *Bf1*) *Cre* mouse line to delete *Sox2* in the olfactory placode. We also disrupted *Sox2* in the developing chick olfactory epithelium by designing a CRISPR-*Sox2* vector and using the CRISPR/Cas9 system. Our results show that *Sox2* deficiency results in upregulation of *Bmp4* expression, disruption of olfactory epithelium development, including loss of the early neurogenic marker *Hes5*, diminished cell cycle progression and proliferation, and complete depletion of the neuronal lineage. Moreover, we also detected increased apoptosis and finally olfactory pit atrophy. Our data further show that mutations in Sox2-binding sites of the *Hes5* promoter result in loss of cis-regulatory activity. Taken together, our findings suggest that Sox2 promotes the olfactory sensory domain by repressing BMP activity, and acts as a regulator of *Hes5* expression and the subsequent onset of neurogenesis.

RESULTS {#s2}
=======

*Sox2* expression becomes progressively restricted to the sensory part of the olfactory epithelium {#s2a}
--------------------------------------------------------------------------------------------------

First, we examined the expression of *Sox2* in the early forming olfactory epithelium in mouse embryos. At embryonic day (E) 9.5, the olfactory placode becomes morphologically visible as an epithelial thickening of the head ectoderm near the telencephalon ([Fig. 1](#DEV153791F1){ref-type="fig"}A). Already at this early stage, olfactory placodal cells express *Sox2* ([Fig. 1](#DEV153791F1){ref-type="fig"}A), and we have previously shown that cells of the neuronal lineage including a few post-mitotic neurons are detectable in the newly formed placode ([@DEV153791C93]). From E10.5, neurogenesis is located in the medial sensory part of the olfactory epithelium ([Fig. 1](#DEV153791F1){ref-type="fig"}B-D,F-H) ([@DEV153791C48]; [@DEV153791C93]). Consistently, at these stages, *Sox2* expression is restricted to the sensory olfactory epithelium, whereas the respiratory part of the olfactory epithelium is *Sox2* negative ([Fig. 1](#DEV153791F1){ref-type="fig"}B-D). We observed the strongest expression of *Sox2* at E10.5, and lower levels at later stages ([Fig. 1](#DEV153791F1){ref-type="fig"}A-D). Fig. 1.***Sox2* and Tuj1 expression patterns in the olfactory epithelium of wild-type mouse.** (A) At E9.5, expression of *Sox2* is detected in the olfactory placode (bracket). (B-D′) From E10.5, *Sox2* expression is restricted to the olfactory sensory epithelium. Black lines in B, C and D′ indicate the border between the sensory and respiratory epithelia. (E) At E9.5, no or only a few Tuj1^+^ neurons are detected in the olfactory placode. (F-H′) From E10.5, Tuj1^+^ neurons are located in the medial part of the sensory epithelium. (D,H) *Sox2* and Tuj1 are also expressed in the vomeronasal organ, an olfactory epithelial derivative (indicated by arrows). D′ and H′ show higher magnifications of the boxed areas in D and H. Scale bars: 100 µm.

Loss of Sox2 inhibits the neuronal lineage in the olfactory placode in mouse {#s2b}
----------------------------------------------------------------------------

To explore the role of Sox2 during early development of the olfactory epithelium and neurogenesis within, we first analysed *Sox2*-deficient embryos and their control littermates. The *Sox2* transgenic mice were generated by breeding mice carrying a *Sox2^flox^* conditional mutation ([@DEV153791C21]) with mice expressing the Cre-recombinase gene under the control of the *Foxg1* promoter ([@DEV153791C37]). The *Sox2^flox/flox^*; *FoxG1^Cre/+^* embryos ([@DEV153791C25]) are hereafter referred to as *Sox2* conditional knockout (cKO) embryos. The expression of *Foxg1* is detected already at the initiation of neurogenesis in the olfactory placode of mice ([@DEV153791C96]), and also at later stages of olfactory development ([@DEV153791C48]). At E9.5, *Sox2* is normally expressed throughout the olfactory placode ([Fig. 2](#DEV153791F2){ref-type="fig"}A). In E9.5 *Sox2* cKO embryos, Cre-mediated deletion of *Sox2* had already occurred in the olfactory placode as well as the telencephalon, but without any clear morphological disturbances of the olfactory placode ([Fig. 2](#DEV153791F2){ref-type="fig"}A). In addition, the olfactory placode markers *Dlx3* and *Dlx5* ([@DEV153791C7]) were expressed throughout the placode in both wild-type and Sox2 cKO embryos at E9.5 ([Fig. S1](Fig. S1)), suggesting that Sox2 is not required for the initial formation of the olfactory placode. Fig. 2.**Loss of neurogenic markers in the *Sox2*-deficient olfactory epithelium.** (A) At E9.5, cells in the control olfactory placode express *Sox2. Hes5*^+^ stem-like progenitors, *Ngn1*^+^ neuronal precursors, *Neurod1*^+^ and Tuj1^+^ post-mitotic neurons are detected in the olfactory placode (*n*=5). In E9.5 *Sox2*-deficient olfactory placodes, no expression of *Sox2*, *Hes5, Ngn1* or *Neurod1*, and a reduced number of Tuj1^+^ cells are detected (*n*=4). The telencephalon is indicated by black asterisks, whereas the olfactory placode is marked by yellow asterisks, as well as by broken white lines. (B) At E10.5, the control olfactory epithelium is invaginated into a pit-like structure and sensory cells express *Sox2*; *Hes5*^+^ stem-like progenitors, *Ngn1*^+^ neuronal precursors, *Neurod1*^+^ and Tuj1^+^ post-mitotic neurons are detected in the epithelium (*n*=6). No or very few aCaspase3^+^ apoptotic cells are detected in the control olfactory epithelium (*n*=6). By E10.5, *Sox2* cKO mutants (*n*=4) do not exhibit an olfactory epithelium, and no expression of any neurogenic markers is detected. A cluster of aCaspase3^+^ apoptotic cells is observed within the area of the disrupted olfactory epithelium. Scale bars: 100 µm.

Next, we analysed whether early stages of olfactory neurogenesis were affected in *Sox2* cKO embryos. At E9.5, the entire neuronal lineage was abolished, with a complete lack of *Hes5^+^* progenitors, *Ngn1^+^* neural precursors and *Neurod1^+^* differentiated neurons in the olfactory placode of *Sox2* cKO mutants, in contrast to control littermates ([Fig. 2](#DEV153791F2){ref-type="fig"}A). Only a few Tuj1^+^ post mitotic neurons were detectable in the mutant olfactory placode ([Fig. 2](#DEV153791F2){ref-type="fig"}A), suggesting a short period of intact neurogenesis before the Cre-mediated *Sox2* ablation occurred. There was no difference in the generation of *Hes5^+^*, *Ngn1^+^*, *Neurod1^+^* or Tuj1^+^ cells between wild-type embryos and heterozygous *Sox2^flox/+^* mutants ([Fig. 3](#DEV153791F3){ref-type="fig"} and data not shown). In addition, *Hes5* was still expressed in the forebrain of *Sox2* cKO mutants ([Fig. 2](#DEV153791F2){ref-type="fig"}A), suggesting that Sox2-mediated regulation of *Hes5* expression is context dependent. Taken together, E9.5 *Sox2* cKO embryos exhibit a loss of cells at various stages of neuronal differentiation in the olfactory placode. Fig. 3.**Decreased neuronal differentiation and increased apoptosis in the *Sox2*-deficient olfactory epithelium.** (A) Tuj1 and aCaspase3 immunofluorescence in E9.5 wild-type, heterozygous *Sox2^flox/+^* and *Sox2* cKO mutants. Arrowheads indicate aCaspase3^+^ cells. (B) No change in the number of Tuj1^+^ neurons or aCaspase^+^ apoptotic cells between the wild-type and heterozygous mice are detected. In contrast, the generation of Tuj1^+^ neurons is decreased and aCaspase3^+^ apoptotic cells are increased in *Sox2* cKO mutants compared with wild-type and heterozygous mice. Statistical analysis of the cell counts in comparison to the total cell number in the olfactory epithelium of E9.5 wild-type (*n*=7), heterozygous (*n*=6) and *Sox2* cKO mutants (*n*=5) are as follows. For Tuj1, wild type versus Het *P*=0.8173, wild type versus KO *P*=0.0263, Het versus KO *P*=0.0412. For aCaspase3, wild type versus Het *P*=0.7847, wild type versus KO *P*\<0.0001, Het versus KO *P*\<0.0001. Error bars represent s.e.m. Student\'s *t*-test, \**P*\<0.05, \*\*\**P*\<0.0001. Scale bar: 100 µm.

The *Sox2*-deficient olfactory placode exhibits changes in cell cycle progression, proliferation and cell death {#s2c}
---------------------------------------------------------------------------------------------------------------

Next, we examined whether changes in proliferation and/or cell death could explain the loss of neurogenic cell types in the Sox2-deficient embryos at E9.5. The number of apoptotic cells, defined by activated (a) Caspase 3, was significantly increased in the olfactory placode compared with wild-type embryos ([Fig. 3](#DEV153791F3){ref-type="fig"}A,B). In contrast, the number of aCaspase3^+^ apoptotic cells was identical between wild-type and heterozygous *Sox2^flox/+^* littermates ([Fig. 3](#DEV153791F3){ref-type="fig"}A,B). Notably, apoptotic Tuj1^+^ neurons were never detected in any of the genotypes ([Fig. 3](#DEV153791F3){ref-type="fig"}A).

To determine the proliferation rate and the progression of the cell cycle in *Sox2* cKO mutants, E9.5 embryos were pulsed for 2 h with BrdU, and for 30 min with EdU starting 1.5 h after the initiation of the BrdU pulse, before being sacrificed. The number of EdU^+^ cells in S-phase in *Sox2* cKO mutants was significantly reduced compared with wild-type and heterozygous *Sox2^flox/+^* embryos ([Table 1](#DEV153791TB1){ref-type="table"}). In addition, the length of the S-phase (Ts) and the total cell cycle length (Tc) were significantly longer in *Sox2* cKO mutants compared with wild-type littermates ([Table 1](#DEV153791TB1){ref-type="table"}). Taken together, one intact *Sox2* allele is sufficient for initial neurogenesis and proliferation in the olfactory placode. In contrast, homozygous *Sox2* deficiency severely affects the developing olfactory epithelium, as shown by diminished neurogenesis, increased apoptosis, reduced proliferation and slower progression of the cell cycle. Table 1.**Proportion of cell cycle parameters and proliferation in the olfactory placode of control and *Sox2* mutants**

The olfactory pit fails to form in Sox2-deficient embryos at E10.5 {#s2d}
------------------------------------------------------------------

To further investigate the effect of *Sox2* deficiency on the development of the olfactory epithelium, *Sox2* cKO mutants and control littermates were analysed at E10.5. In wild-type embryos, the olfactory placode begins to invaginate around E10 and forms the olfactory pit. At E10.5, the olfactory pit is clearly detectable as a depression of the head ectoderm at the most anterior-ventral part of the telencephalon ([Figs 1](#DEV153791F1){ref-type="fig"}B and [2](#DEV153791F2){ref-type="fig"}B). At this stage, *Sox2* expression is restricted to the neuronal sensory part of the olfactory epithelium in wild-type embryos, where the neurogenic markers *Hes5*, *Ngn1*, *Neurod1* and Tuj1 also are expressed ([Fig. 2](#DEV153791F2){ref-type="fig"}B). No aCaspase3^+^ apoptotic cells were detected in the olfactory epithelium of control littermates ([Fig. 2](#DEV153791F2){ref-type="fig"}B).

Strikingly, *Sox2* cKO mutant embryos did not show any morphological structure of the olfactory epithelium at E10.5, correlating with expression of *Sox2* being completely absent in the anterior-ventral part of the head region ([Fig. 2](#DEV153791F2){ref-type="fig"}B). Moreover, no *Hes5^+^* stem-like progenitors, *Ngn1^+^* neural precursors, *Neurod1^+^* differentiated neurons or Tuj1^+^ post-mitotic neurons were detected in the anterior-ventral part of the head region ([Fig. 2](#DEV153791F2){ref-type="fig"}B). Consistent with the observed olfactory pit atrophy, there was a large cluster of aCaspase3^+^ apoptotic cells localized within the area of the disrupted olfactory epithelium ([Fig. 2](#DEV153791F2){ref-type="fig"}B). Thus, at E10.5, *Sox2*-deficient mice completely lack an olfactory epithelium, including any cells of the neuronal lineage, which in part is explained by massive apoptosis in the olfactory epithelial domain.

Sox2 inhibition leads to cell-autonomous downregulation of neurogenic markers and upregulation of respiratory markers {#s2e}
---------------------------------------------------------------------------------------------------------------------

To examine a direct role of Sox2 in neurogenesis, without possible effects caused by severe morphological disruption of the olfactory epithelium, we turned to chick as a model system. *In ovo* chick electroporation assays have the advantage that specific domains of interest in the embryo can be targeted by gene constructs, which lead us to design an electroporation construct to disrupt the *Sox2* gene by using the CRISPR/Cas9-system ([@DEV153791C38]). The onset of neurogenesis in the chick olfactory placode is around stage 14 ([@DEV153791C29]; [@DEV153791C59]). Therefore we electroporated stage 9/10 chick embryos (∼E8.5 in mouse) in the prospective olfactory region with a control vector expressing GFP ([@DEV153791C97]) alone or together with a *Sox2* guide (g) RNA-expressing vector (*Sox2*-CRISPR) and the h*Cas9* vector (the combination of the two latter vectors is herein called *Sox2*-CRISPR/Cas9). A scrambled gRNA construct (*Cont*-CRISPR) together with the *GFP* and h*Cas9* vectors was used as a control. The electroporated embryos were cultured to approximately stage 20-22, and embryos with GFP staining within the olfactory region were collected for analyses.

All embryos electroporated with the *GFP* control vector alone or together with the *Cont-*CRISPR vector displayed normal morphology of the olfactory epithelium, and the expression of *Sox2*, *Hes5* and *Ngn1*, and the numbers of Tuj1^+^ post-mitotic neurons were unchanged compared with the non-electroporated side ([Fig. S2](Fig. S2)). In contrast, in *Sox2*-CRISPR-electroporated embryos Sox2 expression was eliminated in targeted GFP^+^ cells in the olfactory epithelium ([Fig. 4](#DEV153791F4){ref-type="fig"}). In addition, the generation of *Hes5^+^* and *Ngn1^+^* cells and Tuj1^+^ neurons were reduced in the regions of disrupted Sox2 expression in the olfactory epithelium ([Fig. 4](#DEV153791F4){ref-type="fig"}). Consistently, the number of migratory Tuj1^+^ neurons, emanating from the olfactory epithelium ([@DEV153791C29]; [@DEV153791C59]; [@DEV153791C61]), was also reduced ([Fig. 4](#DEV153791F4){ref-type="fig"}). The olfactory pit was also smaller in size in embryos with electroporation efficiency that was more than 50% of the epithelium ([Fig. 4](#DEV153791F4){ref-type="fig"}). In GFP-negative regions expression of Sox2 could still be detected, together with weak expression of *Hes5* and *Ngn1*, pointing to a cell-autonomous effect ([Fig. 4](#DEV153791F4){ref-type="fig"}). Thus, disruption of *Sox2* activity in the chick olfactory epithelium leads to disrupted olfactory neurogenesis. Taken together, the data from mice and chick suggest that the requirement for Sox2 in olfactory neurogenic development is conserved in different vertebrate lineages. Fig. 4.**Inhibition of Sox2 in the chick olfactory epithelium downregulates neurogenic markers in a cell-autonomous manner.** *In ovo* electroporation of stage 9/10 chick embryos in the olfactory epithelium using pCAβ-*EGFP*-m5 and *Sox2-*CRISPR/Cas9 constructs, cultured to approximately stage 20-22. The *Sox2-*CRISPR/Cas9 electroporated olfactory pit is smaller compared with the control non-electroporated side. The generation of *Hes5^+^* and *Ngn1^+^* cells, and the number of Tuj1^+^ neurons are reduced in the regions of disrupted Sox2 expression in the olfactory epithelium compared with the control side (*n*=7). Tuj1^+^ neurons in the olfactory epithelium (outlined) of the control side are indicated with arrows. A reduction in the number of migratory Tuj1^+^ neurons is also detected outside of the olfactory epithelium (outlined) in *Sox2-*CRISPR/Cas9 electroporated embryos. Scale bar: 100 µm.

*Hes5* expression is the earliest indication of neural determination in the olfactory epithelium {#s2f}
------------------------------------------------------------------------------------------------

In relation to sensory versus respiratory patterning of the olfactory epithelium, studies in chick have shown that *Hes5* is expressed prior to other neuronal markers in the olfactory epithelium ([@DEV153791C59]). We therefore examined the expression pattern of neuronal markers in mouse at E9.0. Consistent with the chick data, *Hes5* is already expressed in the olfactory placodal region at E9.0 in mouse, prior to *Ascl1* (previously *Mash1*), *Ngn1*, *Neurod1* and Tuj1 expression ([Fig. S3](Fig. S3)). These results indicate that *Hes5* might be the earliest marker associated with neuronal determination in the sensory olfactory epithelium.

Hes genes are also known to be downstream targets of Notch signalling (reviewed by [@DEV153791C40]; [@DEV153791C43]), raising the possibility that Sox2 promotes *Hes5* expression indirectly through changes in Notch signalling. However, expression of *Notch1* was not detected prior to E10.5 in the olfactory placode of wild-type embryos, and expression of *Notch1* and *Delta1* were unchanged in *Sox2* cKO embryos compared with wild-type littermates ([Fig. S4](Fig. S4)). These results suggest that the initial expression of *Hes5* in the olfactory placode is dependent on Sox2, but not on Notch activity.

*Sox2*-binding sites in the *Hes5* promoter are crucial for cis-regulatory activity {#s2g}
-----------------------------------------------------------------------------------

As the entire neuronal lineage is depleted in the *Sox2*-deficient embryos ([Figs 2](#DEV153791F2){ref-type="fig"} and [4](#DEV153791F4){ref-type="fig"}) and *Hes5* is one of the earliest markers of the neuronal lineage ([@DEV153791C12]; [@DEV153791C70]), we investigated the possibility that Sox2 directly activates *Hes5* expression. Motif searches in the *Hes5* upstream sequence identified one predicted Sox2-binding site located at position −504 bp upstream of the transcription start site and four additional sites between positions −212 and −99. These four sites were conserved between species, as shown by alignment of the mouse, human, chick and ostrich homologous sequences ([Fig. S5](Fig. S5)). In addition, mining of six publicly available ChIP-Seq data sets revealed a peak of Sox2 binding centred to this region of the *Hes5* promoter in human and mouse cells ([Fig. S6](Fig. S6)). These data sets included: mouse embryonic cortex and spinal cord neural progenitors; transformed otic progenitors; forebrain-like ES cell-derived neural progenitors; a human neural stem cell line of ventral midbrain origin; and forebrain-like ES cell-derived neural progenitors ([@DEV153791C35]; [@DEV153791C55]; [@DEV153791C57]; [@DEV153791C69]; [@DEV153791C80]). Together, these data show that Sox2 binds to the *Hes5* promoter region in neural progenitors in both the CNS and PNS.

To further examine whether *Hes5* expression is dependent on Sox2 activity in the CNS, the *Sox2*-CRISPR/Cas9 and GFP constructs were electroporated in the retina at stage 10 and cultured to ∼E4. Under these conditions, the *Hes5* expression in the retina was reduced or completely inhibited ([Fig. 5](#DEV153791F5){ref-type="fig"}). Together, these results suggest that *in vivo* expression of *Hes5* is regulated by Sox2 in regions of both the CNS and PNS. Fig. 5.**Inhibition of Sox2 in the chick retina downregulates *Hes5*.** *In ovo* electroporation of stage 10 chick embryos in the optic vesicle using pCAβ-*EGFP*-m5 and *Sox2-*CRISPR/Cas9 constructs, and cultured to approximately stage 24 (*n*=4). The generation of *Hes5^+^* cells is reduced in the regions of disrupted Sox2 expression in the retina compared with the control side. The *Sox2-*CRISPR/Cas9 electroporated retina is smaller compared with the control non-electroporated side. Scale bar: 100 µm.

To assess whether Sox2 is sufficient for cis-regulatory activation of the *Hes5* promoter, a 527 bp DNA fragment (herein named long promoter) or a 278 bp fragment (herein named short promoter) of the mouse *Hes5* promoter were fused to DNA encoding luciferase ([@DEV153791C62]) ([Fig. 6](#DEV153791F6){ref-type="fig"}A and [Fig. S7A](Fig. S7A)). These *Hes5-luciferase* constructs were transfected in Neuro2a cells alone or together with increasing amounts of a *Sox2* expression construct ([@DEV153791C21]) ([Fig. 6](#DEV153791F6){ref-type="fig"} and [Fig. S7](Fig. S7)). Although a control Sox2-empty vector had no effect on luciferase activity, co-transfection of increasing amounts of a Sox2-expressing vector led to a significant, dose-dependent transactivation of both long and short Hes5 promoter fragments ([Fig. 6](#DEV153791F6){ref-type="fig"} and [Fig. S7](Fig. S7)). As the short promoter corresponded exactly to the peak of Sox2 binding in the ChIP-Seq data sets ([Fig. S6](Fig. S6)), we focused on this region for further investigations. To evaluate a direct action of Sox2 on *Hes5* regulation, all four conserved *Sox2*-binding sites within the short promoter were mutated. Importantly, these mutations abolished the Sox2-dependent induction of *Hes5* promoter activity ([Fig. 6](#DEV153791F6){ref-type="fig"}B), indicating that Sox2 is a direct regulator of *Hes5* expression. Co-transfection with a control vector expressing the neurogenic determinant *Ascl1*, instead of *Sox2*, did not have any effect ([Fig. 6](#DEV153791F6){ref-type="fig"}B), pointing to the Sox2 specificity of the observed activation response. Fig. 6.**Cis-regulatory activity of the *Hes5* promoter is disrupted by mutations in predicted Sox2-binding sites.** (A) The *Hes5* promoter region. The red dotted line indicates the position of the short *Hes5* promoter region cloned in a luciferase vector. Putative Sox2-binding sites (S1 to S5) are indicated by blue dots. The underlined sequences are the most confident Sox2 consensus motifs. A comparison of the S2- to S5-binding sites in the cloned wild-type and mutated *Hes5* promoter fragment is shown at the bottom. (B) Promoter activation assay in Neuro2a cells transfected with a wild-type (wt; blue bars) or mutated (red bars) *Hes5* short promoter cloned in a luciferase vector. Co-transfection of increasing amounts of *Sox2*-expressing vector, but not of a *Mash1*-expressing vector or a control empty vector, resulted in a dose-dependent increase in luciferase activity driven by the wild-type *Hes5* promoter (blue bars), but not by the mutated Hes5 promoter (red bars). *Sox2-* or *Mash1-*expressing vectors did not induce luciferase activity in co-transfection with a promoter-less luciferase vector. The molar ratios compared with the luciferase vector (set at 1) were: +, 1:0.075; ++, 1:0.125; +++, 1:0.25; ++++, 1:0.5. Results are represented as fold-change increase in activity compared with the promoter-less luciferase vector without co-transfected Sox2, which is set at 1. Values are the mean of three independent transfection experiments carried out in triplicate. Error bars represent s.e.m.

The *Hes5* promoter is activated in olfactory epithelial cells *in vivo* {#s2h}
------------------------------------------------------------------------

To further determine whether the *Hes5* promoter can be activated in olfactory epithelial cells, we cloned the short *Hes5* promoter to drive GFP expression ([Fig. S8](Fig. S8)). Subsequently, this construct was electroporated *in ovo* in the olfactory placodal region around stage 10 and embryos were cultured to approximately stage 20-22. As a control the Sox2-negative caudal dorsal ectoderm was electroporated with the *Hes5-*GFP construct. During these conditions, GFP expression was detected in the olfactory epithelium, but not in caudal dorsal ectodermal cells ([Fig. S8](Fig. S8)), providing evidence that the *Hes5* promoter can be activated in olfactory epithelial cells *in vivo*.

Ectopic *Hes5* expression is not sufficient to induce neurogenic character in respiratory epithelium {#s2i}
----------------------------------------------------------------------------------------------------

To examine whether *Hes5* has the potential to ectopically induce neurogenesis in prospective respiratory cells or the head ectoderm near the olfactory region, we continued to take advantage of the chick model system. A GFP-construct was electroporated together with a *Hes5-*overexpression construct ([@DEV153791C39]) in the respiratory ectoderm and head ectoderm near the olfactory region in stage 10/11 embryos. The electroporated embryos were cultured to approximately stage 22 and embryos with GFP staining within the olfactory regions were collected for analyses. All embryos electroporated exhibited a normal morphology of the olfactory region, and ectopic *Hes5* activity in the respiratory domain was not sufficient to inhibit *Msx1/2* expression or to induce neurogenesis, which are marked by *Ngn1* and Tuj1 in comparison with the non-electroporated control side ([Fig. S9](Fig. S9)). Thus, our results suggest that ectopic *Hes5* expression is not sufficient to trigger neurogenesis in the respiratory epithelium.

Sox2 restricts the respiratory domain and promotes the neuronal lineage independently of BMP activity {#s2j}
-----------------------------------------------------------------------------------------------------

The suppression of the neuronal lineage in the Sox2-deficient olfactory epithelium might be due to an early patterning defect. It is known that during early development, the olfactory epithelium becomes restricted into an anterior-medial sensory region and a posterior-lateral respiratory domain ([@DEV153791C16]; [@DEV153791C60]). This division of the nasal epithelium is regulated by FGF and BMP signals that promote sensory and respiratory cell identities, respectively ([@DEV153791C60]). Therefore, we analysed the expression of *Fgf8*, *Bmp4* and the olfactory respiratory marker *Msx2* ([@DEV153791C60]) in E9.5 and E10.5 *Sox2* cKO mutants and control littermates.

At E9.5, *Fgf8*, *Bmp4* and the respiratory marker *Msx2* were expressed in an overlapping pattern in the lateral parts of the olfactory placode in control embryos ([Fig. 7](#DEV153791F7){ref-type="fig"}A). In addition, in E10.5 control embryos, at the centre of the olfactory pit, *Fgf8* and *Bmp4* expression overlaps in the lateral edges of the epithelium where *Msx2* expression is also detected ([Fig. 7](#DEV153791F7){ref-type="fig"}B). In contrast, in *Sox2* cKO mutants, *Fgf8* expression was mildly decreased, but still restricted to the edges of the placode, whereas *Bmp4* and *Msx2* expression were expanded to the entire olfactory placode ([Fig. 7](#DEV153791F7){ref-type="fig"}A), which is consistent with the finding that BMP signals induce *Msx2*^+^ respiratory cells ([@DEV153791C60]). Moreover, in E10.5 *Sox2* cKO mutants, *Fgf8*, *Bmp4* and *Msx2* were co-expressed in a small area in the anterior-ventral part of the head region ([Fig. 7](#DEV153791F7){ref-type="fig"}B) corresponding to the aCaspase3-rich domain ([Fig. 2](#DEV153791F2){ref-type="fig"}B). In addition, in the *Sox2*-deficient embryos, *Msx2* was expressed throughout the surface ectoderm without any interruptions and in the adjacent mesenchyme ([Fig. 7](#DEV153791F7){ref-type="fig"}B). These results indicate that *Sox2* acts as a negative regulator of *Bmp4* expression to restrict the respiratory domain and favour olfactory sensory cell identity in the nasal epithelium. Fig. 7.**Increased *Bmp4* and *Msx2* expression in the Sox2-deficient olfactory sensory epithelium.** (A) At E9.5, in control embryos (*n*=5), *Fgf8*, *Bmp4* and *Msx2* expression are overlapping at the edges of the olfactory placode, the prospective respiratory region. In *Sox2* cKO mutants (*n*=4), *Bmp4* and *Msx2* expression is expanded into the entire olfactory placode, and *Fgf8* expression is mildly decreased at the edges of the placode. (B) At E10.5, in the centre of the olfactory pit of control embryos (*n*=5), *Fgf8*, *Bmp4* and *Msx2* expression overlap in the lateral edges of the epithelium. In E10.5 *Sox2* cKO mutants (*n*=4), *Fgf8*, *Bmp4* and *Msx2* are co-expressed in a small cluster in the anterior-ventral part of the head region, and *Msx2* is also expressed in the adjacent mesenchyme and surface ectoderm. Scale bars: 100 µm.

We further examined this issue using *Sox2*-CRISPR-electroporations in the prospective olfactory region in chick embryos. In Sox2-CRISPR-electroporated embryos, *Bmp4* and Msx1/2 expression expanded into the Sox2 deficient region of the nasal epithelium, which in some cases also were less invaginated ([Fig. 8](#DEV153791F8){ref-type="fig"}A). To test whether inhibition of neurogenesis is merely a result of the upregulated BMP activity, we electroporated Sox2-CRISPR/Cas9 together with a Noggin construct, which inhibits BMP signals ([@DEV153791C87]). Under these conditions, the olfactory pit formation was clearly disrupted ([Fig. 8](#DEV153791F8){ref-type="fig"}B), which is in agreement with our previous publications showing that BMP activity is regulating epithelial invagination ([@DEV153791C42]). Moreover, the expression of Msx1/2 was suppressed in electroporated cells, and Sox2-deficient cells did not express *Hes5* and *Ngn1* ([Fig. 8](#DEV153791F8){ref-type="fig"}B), suggesting that Sox2 is required for the neurogenic lineage in the absence of BMP activity. Taken together, our results show that Sox2 activity plays a crucial role in the generation of the neurogenic lineage in the nasal epithelium, in part by restricting BMP activity and thereby promoting the sensory domain, and by regulating the onset of *Hes5* expression. Fig. 8.***Bmp4* expression is upregulated in Sox2-deficient cells, but in the absence of BMP activity Sox2 is still required for the neurogenic lineage.** (A,B) *In ovo* electroporation of stage 9/10 chick embryos in the olfactory epithelium using pCAβ-*EGFP*-m5 and *Sox2-*CRISPR/Cas9 constructs alone (A; *n*=5) or together with a Noggin vector (B; *n*=4), and cultured to approximately stage 20-22. The electroporated olfactory pit is smaller compared with the control non-electroporated side. (A) The expression of *Bmp4* and Msx1/2 is expanded in the Sox2-deficient region of the nasal epithelium. (B) In regions of suppressed Sox2 and BMP activity, observed by loss of Sox2 and Msx1/2 expression, respectively, *Hes5* and *Ngn1* expression is reduced. A few *Hes5^+^* and *Ngn1^+^* cells are detected in regions with remaining Sox2 activity (arrows). Scale bar: 100 µm.

DISCUSSION {#s3}
==========

Here, we present evidence that Sox2 activity plays a crucial role in the early development of the neural domain of the olfactory epithelium and neurogenesis within, in part by restricting *Bmp4* expression and respiratory cell identity. Our data show that mutations of the Sox2-binding sites in the *Hes5* promoter suppress cis-regulatory activity, suggesting that Sox2 might regulate neurogenesis cell-autonomously via direct activation of the *Hes5* gene. Consistently, blockade of Sox2 activity in the olfactory domain results in a complete depletion of the entire neuronal lineage. Furthermore, our results show that the *Sox2-*deficient olfactory epithelium displays diminished cell cycle progression and proliferation, a dramatic increase in apoptosis and finally olfactory pit atrophy.

By analysing *Sox2* conditional knockout mice, our results show that in the absence of *Sox2*, cells of the neuronal lineage in the olfactory epithelium already fail to develop at E9.5, the placode stage. This lack of neurogenesis was not caused by a delay in the generation of neural progenitors, because, also at later stages, no *Hes5*^+^ neural progenitor cells could be observed. Moreover, the complete inhibition of neural progenitors and precursors with only a few post-mitotic neurons detected at E9.5 provides evidence that neural progenitors do not differentiate prematurely. Despite the absence of the neuronal lineage, at this stage the morphology of the placode appeared normal and cells expressed the placode markers *Dlx3* and *Dlx5* ([@DEV153791C7]). Sox2 has also been shown to be crucial for neurosensory precursor formation in the otic placode, giving rise to the inner ear ([@DEV153791C17]; [@DEV153791C50]; [@DEV153791C67], [@DEV153791C68]). Moreover, in chick, the use of a dominant repressor *Sox3* construct, another SoxB1 family member, blocks neurogenesis in the epibranchial placodes ([@DEV153791C88]). Thus, Sox2 and other SoxB1 family members appear to be crucial for embryonic neurogenesis in the placodes.

Besides the finding of suppressed neurogenesis, our results indicate a drastic increase of apoptotic cell death in the Sox2-deficient olfactory epithelium in mouse. These data suggest that Sox2 might play a role in regulating apoptosis. Consistently, previous studies have shown an increased apoptotic cell death in both the ventral telencephalon and in the hippocampus in *Sox2* conditional knockout mouse ([@DEV153791C21]; [@DEV153791C25]). Moreover, recent studies using *in vitro* and *in vivo* assays of neural stem cell and human lung cancer cell survival have demonstrated that silencing of *Sox2* results in decreased levels of survivin, a member of the inhibitor of apoptosis protein family, and induced apoptosis ([@DEV153791C15]; [@DEV153791C23]). Further studies regarding the potential role for *Sox2* in protecting neural stem and progenitor cells from apoptosis will be interesting to follow.

The nasal epithelium is divided into a neurogenic sensory region and a non-neurogenic respiratory domain ([@DEV153791C16]; [@DEV153791C60]). Our previous study has shown that BMP signals promote the specification of respiratory epithelial cells in the nasal epithelium, and that Msx1/2 and *Id3* can be used to detect respiratory epithelial cells ([@DEV153791C60]). Furthermore, the same study provided evidence that BMP and FGF signals act in an opposing manner to regulate the respiratory versus sensory epithelial cell fate decision ([@DEV153791C60]). Our results now show that in the absence of Sox2 activity, *Bmp4* and *Msx2* expression are expanded in the Sox2-disrupted olfactory epithelial domain. These results indicate that Sox2 acts as a negative regulator for *Bmp4* expression to restrict the respiratory domain and define the sensory domain of the nasal epithelium. However, inhibition of BMP activity in the Sox2-deficient olfactory cells, could not rescue neurogenesis, indicating a direct requirement for Sox2 in establishing the neuronal lineage in the olfactory epithelium. Our data also show that ectopic *Hes5* activity is not sufficient to inhibit respiratory cell identity or induce neurogenic properties in the respiratory domain, further indicating that Sox2 plays a crucial role in the establishment of the olfactory sensory territory. Future studies are required to fully understand the epistasis and hierarchy between Sox2, Hes5, Bmp4 and respiratory markers such as Msx2, and to provide deeper knowledge regarding the early development of the sensory and non-sensory nasal epithelium.

Our results indicate that in the absence of *Sox2,* the proliferative sensory progenitor pool in the olfactory epithelium is not established, resulting in complete loss of the neuronal lineage in the olfactory epithelium. Our data in chick provide evidence that inhibition of Sox2 leads to downregulation of neuronal markers in a cell-autonomous manner. Moreover, the *Sox2-*deficient olfactory epithelium exhibit reduced proliferation and a slower progression of the cell cycle. This correlates well with previous work in the olfactory epithelium that has shown that rapid proliferation occurs in the medial neurogenic part of the olfactory epithelium, in which Sox2 is highly expressed together with *Hes5* and *Mash1* ([@DEV153791C89]; [@DEV153791C94]). In contrast, proliferation in the lateral part of the olfactory epithelium proceeds in a slow and symmetric manner ([@DEV153791C89]; [@DEV153791C94]). In addition, it has been shown that ectopic overexpression of Sox2 in the lateral olfactory epithelium enhances neurogenesis and significantly increases the generation of post-mitotic neurons ([@DEV153791C89]). Notably, at adult stages, Sox2 expression is maintained in stem cells in the olfactory epithelium ([@DEV153791C1]; [@DEV153791C21]; [@DEV153791C33]; [@DEV153791C46]; [@DEV153791C52]; [@DEV153791C73]), and the olfactory epithelium has the potential to recover almost completely after injury (reviewed by [@DEV153791C83]). A recent publication using an olfactory epithelial regenerative assay in adult *Sox2* conditional knockout mice, has shown that deletion of *Sox2* reduces the production of olfactory sensory neurons during regeneration and suggests that Sox2 expands the pool of neuronal progenitors ([@DEV153791C73]). These data are consistent with our findings at embryonic stages that Sox2 is required for neurogenesis in the olfactory epithelium to establish and/or maintain neuronal progenitors during normal development. Taken together, these data indicate that Sox2 is essential for the neurogenic capacity to establish, maintain and expand the neuronal progenitor pool.

Another study has suggested that both SoxB1 members and Notch signalling play key roles during the maintenance of neural precursors in the CNS ([@DEV153791C39]). Moreover, in the otic placodes, early Notch activity is required to maintain and restrict Sox2 expression to establish the pro-sensory otic region ([@DEV153791C17]; [@DEV153791C67]). We now show that *Sox2* is expressed in the olfactory placode prior to *Notch1* and *Delta1* (*Dll1*) expression. Ours and other studies have shown that at later stages, from E10.5 and onwards, *Notch1* and *Delta1* expression are increased in the neurogenic part of the nasal epithelium ([@DEV153791C13]; [@DEV153791C82]; [@DEV153791C94]), which indicate that Notch activity is required to maintain and/or restrict ongoing olfactory neurogenesis. In addition, our results show that *Hes5* is already expressed in prospective olfactory epithelial cells of the head ectoderm at E9.0, prior to the expression of other neuronal markers such as *Ascl1*, *Ngn1*, *Neurod1* and Tuj1, which is in agreement with the expression pattern in chick ([@DEV153791C59]). Thus, *Hes5* appears to be the earliest known marker associated with neuronal determination of the olfactory epithelium. Previous studies in mice, at around E10.5-E12.5, have presented a model of crossregulation between *Hes1*, *Hes5* and *Ascl1* for the control of neuronal differentiation in the olfactory epithelium ([@DEV153791C13], [@DEV153791C12], [@DEV153791C11]). *Hes1* has been suggested to regulate the neural progenitor domain, including *Ascl1* transcription in the olfactory placode, whereas *Hes5* expression is suggested to be dependent on *Ascl1* activity, likely via the Notch pathway ([@DEV153791C12]). Our results, presenting the expression of *Hes5* at E9.0 in the absence of *Ascl1*, indicate that the initial upregulation of *Hes5* is independent of *Ascl1* activity. In addition, although *Hes5* expression is reduced in *Ascl1* knockout mice, there are domains of *Hes5*-positive cells and ongoing neurogenesis present in the *Ascl1*-deficient olfactory epithelium ([@DEV153791C12], [@DEV153791C11]). It is possible that the remaining *Hes5*-positive cells and neurogenic olfactory domain in the *Ascl1* knockout mice are generated from the early *Ascl1*-independent *Hes5* cells, and that, at later stages, the regulation of *Hes5* expression and ongoing olfactory neurogenesis involves an *Ascl1* and Notch pathway control mechanism. The fact that all three individual knockout mice of *Hes1*, *Hes5* and *Ascl1* generate olfactory neurons ([@DEV153791C13], [@DEV153791C12], [@DEV153791C11]) points to redundant functions of these genes during olfactory neurogenesis and that other upstream molecules are important to determine the olfactory neurogenic domain.

Our study suggests that *Sox2* is activating *Hes5* expression by regulating the Hes5 promoter. We show that disruption of Sox2 activity in the olfactory epithelium, part of the PNS, and the retina, part of the CNS, results in loss of *Hes5* expression. In agreement with this, *Hes5* expression is suppressed in conditionally ablated Sox2 retinal cells in mouse ([@DEV153791C86]). Interestingly, regulation of the *Hes5* promoter by SoxC transcription factors (Sox4, Sox11, Sox12) was recently proposed to mediate a crucial role for retinogenesis ([@DEV153791C54]). As Sox2 has been shown to bind neural lineage-specific genes, which later are bound and activated by SoxC factors in differentiating neurons ([@DEV153791C4]), our observation might point to *Hes5* as a possible mediator of Sox2 function also in retinogenesis. Our mining of six available ChIP-Seq data sets ([@DEV153791C35]; [@DEV153791C55]; [@DEV153791C57]; [@DEV153791C69]; [@DEV153791C80]) revealed a peak of Sox2 binding to the *Hes5* promoter in neural progenitors in both the CNS and PNS in human and mouse cells. In agreement with our findings, a study in zebrafish using chromatin immunoprecipitation analysis of the Hes-class bHLH gene *her3* and *hesx1* genes suggests a direct regulation of these genes by SoxB1 members ([@DEV153791C71]). In the same study, a quadruple knockdown of the four SoxB1 genes *sox2*/*sox3*/*sox19a*/*sox19b* followed by gene expression analyses indicated that the SoxB1 members promote neural differentiation by regulating the Hes-class bHLH gene *her3* and the proneural-class bHLH genes *ngn1* ([@DEV153791C71]). In addition, a study of the inner ear in chick has suggested that Sox2 (a SoxB1 family member) activates Ngn1, which in turn act as a repressor for Hes genes ([@DEV153791C19]). This mechanism might also regulate neurogenesis in the olfactory epithelium. Although in the *Sox2* cKO olfactory placode, *Hes5* and *Ngn1* expression was never detected, indicating that, in the absence of *Sox2*, cells of the neuronal lineage are not specified in the olfactory epithelium. In a similar fashion, it has been suggested that *Sox2* directly activates the transcription of the bHLH proneural gene *Atoh1* (previously *Math1*) ([@DEV153791C5]; [@DEV153791C95]) to define the sensory domain of the otic epithelium ([@DEV153791C68]). In conclusion, our findings indicate that the establishment of sensory progenitor cells in the olfactory epithelium requires Sox2-directed downregulation of *Bmp4* and upregulation of *Hes5* expression.

MATERIALS AND METHODS {#s4}
=====================

Mouse and chick embryos {#s4a}
-----------------------

The conditional *Sox2-*deficient mouse line (*Sox2* cKO), described previously ([@DEV153791C25]), was generated by crossing *Sox2^flox/+^* mice ([@DEV153791C21]) with *Foxg1-Cre* mice ([@DEV153791C37]). *Foxg1*-mediated *loxP* recombination in *Sox2* mutants occurred in the telencephalon and discrete head regions, including the olfactory epithelium. The generation, genotyping and phenotyping of *Sox2* cKO mice and their control littermates were performed as previously described ([@DEV153791C25]). The use of *Sox2* cKO and control mice was part of experimental protocols approved by the Italian Ministry of Health according to Legislative Decree 116, conforming to European legislation (authorization number 357/2016-PR). Fertilized white Lohman chicken eggs were obtained from Strömbäcks Ägg (Vännäs, Sweden). Chick embryos were staged according to the protocol of [@DEV153791C36].

*In situ* hybridization and immunohistochemistry {#s4b}
------------------------------------------------

For the use of *in situ* RNA hybridization and immunohistochemistry, embryos were fixed in 4% PFA, transferred to 25% sucrose, embedded and stored at −80°C until cryosectioned at 10 µm on consecutive slides. *In situ* RNA hybridization was performed essentially as previously described ([@DEV153791C92]). Applied mouse digoxigenin-labelled probes were: *Sox2* ([@DEV153791C24]), *Hes5* ([@DEV153791C58]), *Ngn1* (a gift from G. Fishell, New York University, USA), *Neurod1* ([@DEV153791C11]), *Msx2* ([@DEV153791C41]), *Bmp4* ([@DEV153791C41]) and *Fgf8* (a gift from H. Edlund, Umeå University, Sweden). Applied chick digoxigenin-labelled probes were: *Bmp4* ([@DEV153791C30])*, Dlx3*, *Dlx5* and *Hes5* (*Hes5-1*) ([@DEV153791C26]), *Ngn1* ([@DEV153791C75]) and *NeuroD* ([@DEV153791C3]).

Immunohistochemistry was performed using standard protocols. Antibodies used were: anti-Tuj1 (neuronal class III β-Tubulin, 1:500, Covance, MMS-435P), anti-Msx1/2 (1:10, DSHB, 4G1), anti-Ki67 (1:1000, Becton Dickinson, 556003), anti-BrdU (1:50, DSHB, G3G4), anti-Sox2 (1:1000, a gift from T. Edlund, Umeå University, Sweden), anti-GFP (1:600, Aves Labs, 1010), anti-cleaved caspase 3 (1:1000, Cell Signaling, 9961) and anti-phospho-Histone H3 (1:500, Millipore, 06-570). Alexa Fluor secondary antibodies (1:400, Molecular Probes, A32723, A11034, A11032) were used and nuclei were stained using DAPI (1:400-600, Sigma, D-9542). Briefly, sections were blocked in 10% foetal calf serum (FCS) prior to primary antibody incubation overnight at 4°C.

The protocol for BrdU/EdU histochemistry was as follows. Prior to blocking and antibody incubation, sections used for BrdU/EdU histochemistry were washed briefly in TBST at room temperature, for 10 min in ice-cold 1 M HCl at 4°C, for 20 min in 2 M HCl at 37°C, for 10 min in 0.1 M sodium borate buffer (pH 8.5) at room temperature and briefly in TBST at room temperature. Blocking was performed in 10% FCS followed by incubation with anti-BrdU antibody overnight at room temperature. EdU detection was performed according to the manufacturer\'s protocol (Molecular Probes). *In situ* and immunohistochemistry slides were mounted with glycerol or fluorescent mounting medium (Dako), respectively.

Determination of cell cycle parameters in mouse embryos {#s4c}
-------------------------------------------------------

E9.5 pregnant dams were first injected with bromodeoxyuridine (BrdU, Sigma) and 1.5 hours (h) later injected with ethynyldeoxyuridine (EdU, Molecular Probes) for 30 min, both at 50 µg/g body weight, before embryo collection. BrdU/EdU histochemistry details are given above. The cell cycle parameters were determined as previously described ([@DEV153791C63]; [@DEV153791C78]). The 2 h BrdU pulse labelled nuclei in S phase and G2/M phases, whereas the 30 min EdU pulse labelled S-phase nuclei. The BrdU^+^/EdU^−^ nuclei correspond to cells leaving S phase during the 1.5 h period. The S phase (Ts) was calculated using the formula: Ts=1.5×(number of EdU^+^ cells/number of BrdU^+^/EdU^−^ cells). The total cell cycle length (Tc) was calculated as: Tc=Ts×(total cell number/number of EdU^+^ cells) ([@DEV153791C63]; [@DEV153791C78]). At E9.5, Ki67 immunostaining, which defines proliferating cells ([@DEV153791C98]), indicated that virtually all olfactory placodal cells proliferate ([Fig. S10](Fig. S10)). Subsequently, the total number of proliferating cells was estimated by counting all DAPI nuclei in the placode area.

CRISPR/Cas9 targeting of Sox2 {#s4d}
-----------------------------

The construct pUC19-U6-*Sox2*-gRNA was engineered to overexpress a CRISPR guide (g)RNA directed to the Sox2 locus under the control of the U6 promoter. Briefly, the gRNA 5′-GTTTTAGAGCTAGAAATAGCAAG TTAAAATAAGGCTAGTCCGTTATCAACTTGAAAAAGTGGCACCGAGTCGGTGCTTTTTTT-3′ ([@DEV153791C31]) was cloned in a pUC19 vector (Invitrogen). A 20 bp target sequence, corresponding to positions 537-556 of the chicken *Sox2*-coding sequence (sequence below) was cloned in front of the gRNA in the pUC19 vector by *Bbs*I digestion. Oligonucleotides for the *Sox2*-CRISPR construct were as follows: *Sox2*-forward, 5′-GGGGGCGGGAGGTTTCAGCT-3′; *Sox2*-reverse: 5′-AGCTGAAACCTCCCGCCCCC-3′.

The control construct pUC19-U6-*Cont*-gRNA was designed in a similar way replacing the 20 bp target sequence by a random nucleotide sequence as follows: *Cont*-gRNA-forward, 5′-GGACTGCTACGATCTACACC-3′; *Cont*-gRNA-reverse, 5′-GGTGTAGATCGTAGCAGTCC-3′

The oligonucleotides were diluted to a final 2 mM concentration in annealing buffer containing 100 mM potassium acetate and 30 mM Hepes (pH 7.4), denatured at 95°C for 3 min and cooled to 37°C for annealing over 2-3 h. The sequence of the construct was verified by Sanger sequencing.

*In ovo* electroporation of chick embryos {#s4e}
-----------------------------------------

Stage 8-10 chick embryos were electroporated in the olfactory placode region, and stage 10/11 chick embryos were electroporated in the head ectoderm in and around the olfactory placodal region, or the prospective retina by applying three pulses (9-12 V, 25 ms duration, 1 s interval), adapted to previous experiences ([@DEV153791C93]). Vectors used were: pCAβ-*EGFP*m5 ([@DEV153791C97]), pCAG-hCas9 vector (addgene \# 51142), pUC19-*Sox2*gRNA, pUC19-*Cont*-gRNA, pCAGGS-*Hes5* ([@DEV153791C39]) and pMiwIII--Noggin ([@DEV153791C87]), all at a concentration of 1.0 μg/μl ([@DEV153791C87]). Inhibition of BMP signalling by the Noggin construct has previously been verified ([@DEV153791C60]; [@DEV153791C74]). The constructs were transferred using an Electro Square Porator ECM 830 (BTX). After electroporation, the eggs were re-incubated to approximately stage 20-22 (olfactory epithelium) or stage 24 (retina). Viable embryos with GFP expression in the region of interest were selected for further analysis.

Promoter analysis and ChIP-seq data mining {#s4f}
------------------------------------------

The 5-prime upstream sequence of mouse, human, chick and ostrich were retrieved from the current assembly available at Ensembl and Avianbase. Putative Sox2-binding sites were predicted using the PROMO tool ([@DEV153791C20]). The alignment in [Fig. S4](Fig. S4) was performed using MAFFT ([@DEV153791C47]). The predicted Sox2-binding sequence was compared with consensus Sox2-binding sequences derived from the JASPAR database ([@DEV153791C65]).

For analysis of available ChIP-seq data, pre-computed coverage tracks were obtained from the Cistrome database (cistrome.org/db/) and viewed in the UCSC genome browser. The datasets with SRA accession numbers SRR945967, SRR1929985, SRR1616842, SRR3151474, SRR3151475 and SRR630003 were used. For data not available on cistrome.org, raw reads were mapped and processed into coverage track files as specified on the Cistrome homepage (cistrome.org/db/\#/about).

Luciferase constructs {#s4g}
---------------------

A wild-type 278 bp region, including four Sox2-binding sites, of the mouse *Hes5* promoter and a mutated *Hes5* promoter were cloned immediately upstream of the luciferase gene into the TK-LUC vector, from which the minimal TK promoter had been deleted ([@DEV153791C25]). In the mutated *Hes5* promoter, all four Sox2-binding sites (underlined) were mutated by changing 3 bp/binding site (italic): 5′-GGCGCGGGGCTCTCAGCATCAGGCCCCGGGATGCTAATGAGGGCGAGCGCGTTCCCACAGCCCGG[ACA*CCC*TG]{.ul}CCGCGCGGCCCACCTGCTCCTCGGGGAGCGA[CCA*CCC*TG]{.ul}CCCGCGCCAATTCACAGGCAATTTAGCGTGCGCTAATGGGCCGGCG[CCT*CCC*TG]{.ul}CGGCCGGCGCCG[CCA*CCC*GC]{.ul}CGCCGAGTGTGGGAACGGCCGCGGCGCCCGGACCCCAGGCGCCGGGCCGCTGCCCGCGCCTATATAGGGCTGGCGTGCTGGGGTCCAGGTCG 3′ (ordered from Sigma).

Transfection experiments {#s4h}
------------------------

Transfection experiments were performed essentially as previously described ([@DEV153791C62]). Specifically, Neuro-2a (N2a) cells were plated in Minimum Essential Medium Eagle (MEM; Sigma), supplemented with 10% foetal bovine serum, L-glutamine, penicillin and streptomycin. For transfection, cells were plated in 12-well-plates at 1.5×10^5^ cells/well, and transfected the following day with Lipofectamine 2000 (Invitrogen). According to the manufacturer\'s instructions medium in each well was replaced with 1 ml of MEM medium (with no addition) mixed with 2 µl of Lipofectamine 2000, and DNA. We used a fixed amount of 300 ng of luciferase reporter plasmid for each well, with increasing amount of *Sox2*-expressing vector, or *Mash1*-expressing vector ([@DEV153791C21]; [@DEV153791C62]), or the corresponding control 'empty' vectors (not containing the transcription factor\'s cDNA), in the following luciferase vector: expressing vector molar ratios (indicated as in [Fig. 6](#DEV153791F6){ref-type="fig"} and [Fig. S7](Fig. S7)): \|, 1:0.025; ⊢, 1: 0.050; +, 1:0.075; ++, 1:0.125; +++, 1:0.25; ++++, 1:0.5. The pBluescript vector was added to each transfection to equalize the total amount of transfected DNA to a total of 800 ng in each reaction. After 24 h, total cellular extracts were prepared and Luciferase activity was measured with a Promega Luciferase Assay System, according to the manufacturer\'s instructions.

Statistical analysis and imaging {#s4i}
--------------------------------

The total number of Tuj1^+^ and aCaspase3^+^ cells was determined by counting the number of DAPI^+^ nuclei. The graphs represent the mean number±s.e.m. as percentage of the total cell number if not stated otherwise. Significance was determined using Student\'s *t*-test with \**P*\<0.05, \*\**P*\<0.01 and \*\*\**P*\<0.0001 accepted as statistically significant. Quantification and image generation was performed using a Nikon Eclipse E800 microscope for simultaneous Epi-fluorescence/DIC observations, equipped with a CCD camera connected to a PC (Nikon Imaging Software NIS-Elements). Images were processed using Photoshop CS2 (Adobe). BrdU^+^ and BrdU/EdU double-labelled cells were counted in the E9.5 olfactory placode. *Sox2* cKO mutant embryos were compared with age-matched wild-type and heterozygous *Sox2^flox/+^* littermates. All data were analysed using Prism GraphPad software. For the transfection assay, results are presented as the mean±s.e.m.
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